CATALIST-listed AOXIN Q&M records 21% growth in revenue for full year ended 31 December 2021
– EBITDA grew 47% for 12 months ended 31 Dec 2021– Proposed listing of 49%-owned Acumen Diagnostics on NASDAQ will enhance AOXIN’s shareholder value– Growth trend in revenue expected to continue as COVID-19 situation in China improves SINGAPORE, Feb 23, 2022 – (ACN Newswire) – Catalist listed Aoxin Q&M Dental Limited (“Aoxin” or “the Group”), today announced a 20.8% […]










